share_log

Chardan Capital Maintains Buy on Passage Bio, Lowers Price Target to $11

Benzinga Real-time News ·  Dec 15, 2022 06:17

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $18 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment